Comparison of MEGX (monoethylglycinexylidide) and antipyrine tests in patients with liver cirrhosis.
The aim of the study was to compare the feasibility of the MEGX (monoethylglycinexylidide) and antipyrine tests in reference to standard biochemical parameters used for liver assessment in cirrhotic patients. The study was carried out in 44 subjects: 14 healthy controls and 30 cirrhotic patients classified according to the Child-Pugh's score to subgroups A (n=11), B (n=12) and C (n=7). All subjects underwent two dynamic liver tests, i.e. MEGX (monoethylglycinexylidide) and antipyrine test in a crossover schedule with at least 5-day interval. For the MEGX, lidocaine was administrated intravenously, at a dose of 1 mg/kg, and blood samples for MEGX assay were collected after 15 minutes. MEGX concentrations were measured by fluorescence polarization immunoassay. The antipyrine concentrations were evaluated following a single oral administration of 1000 mg antipyrine. The blood was sampled for 24 hours after the drug administration, and antipyrine concentrations were measured spectrophotometrically. Standard biochemical parameters used for liver assessment were measured by means of routine laboratory methods. It was concluded that in patients liver with cirrhosis, liver dynamic tests were better predictors of hepatic function. The MEGX test was more feasible in clinical setting, but it was noted that antipyrine test was more sensitive in staging liver cirrhosis.
Wojcicki
J
J
Department of Experimental and Clinical Pharmacology, Pomeranian Academy of Medicine, Szczecin, Poland.
Kozlowski
K
K
Drozdzik
M
M
Wojcicki
M
M
D000328:Adult; D000368:Aged; D000983:Antipyrine; D004798:Enzymes / Q000097:blood; D005260:Female; D006207:Half-Life; D006801:Humans; D008012:Lidocaine / Q000031:analogs & derivatives*; D008103:Liver Cirrhosis / Q000175:diagnosis*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D012016:Reference Values
D004798:Enzymes; D008012:Lidocaine; C001173:monoethylglycinexylidide; D000983:Antipyrine